- Home
- TXG vs INVA Comparison
TXG vs INVA Comparison
Compare TXG & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXG
- INVA
- Stock Information
- Founded
- TXG 2012
- INVA 1996
- Country
- TXG United States
- INVA United States
- Employees
- TXG N/A
- INVA N/A
- Industry
- TXG Biotechnology: Laboratory Analytical Instruments
- INVA Biotechnology: Pharmaceutical Preparations
- Sector
- TXG Industrials
- INVA Health Care
- Exchange
- TXG Nasdaq
- INVA Nasdaq
- Market Cap
- TXG 1.3B
- INVA 1.3B
- IPO Year
- TXG 2019
- INVA 2004
- Fundamental
- Price
- TXG $14.11
- INVA $18.72
- Analyst Decision
- TXG Buy
- INVA Strong Buy
- Analyst Count
- TXG 12
- INVA 3
- Target Price
- TXG $14.13
- INVA $40.33
- AVG Volume (30 Days)
- TXG 3.7M
- INVA 907.8K
- Earning Date
- TXG 08-07-2025
- INVA 08-04-2025
- Dividend Yield
- TXG N/A
- INVA N/A
- EPS Growth
- TXG N/A
- INVA N/A
- EPS
- TXG N/A
- INVA N/A
- Revenue
- TXG $624,662,000.00
- INVA $369,844,000.00
- Revenue This Year
- TXG N/A
- INVA $3.75
- Revenue Next Year
- TXG $5.69
- INVA $12.62
- P/E Ratio
- TXG N/A
- INVA N/A
- Revenue Growth
- TXG N/A
- INVA 18.70
- 52 Week Low
- TXG $6.78
- INVA $16.67
- 52 Week High
- TXG $24.76
- INVA $22.00
- Technical
- Relative Strength Index (RSI)
- TXG 68.91
- INVA 36.02
- Support Level
- TXG $11.45
- INVA $19.35
- Resistance Level
- TXG $14.16
- INVA $20.58
- Average True Range (ATR)
- TXG 0.71
- INVA 0.46
- MACD
- TXG 0.08
- INVA -0.07
- Stochastic Oscillator
- TXG 93.01
- INVA 3.63
About TXG 10x Genomics Inc.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.